FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents

Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.)

Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

Related Categories:

Drug, Bio-affecting And Body Treating Compositions


Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Binds Antigen Or Epitope Whose Amino Acid Sequence Is Disclosed In Whole Or In Part (e.g., Binds Specifically-identified Amino Acid Sequence, Etc.)



Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use
01/22/15 - 20150023969 - The present invention provides isolated polypeptides isolatable from a Staphylococcus spp. Also provided by the present invention are compositions that include one or more of the polypeptides, and methods for making and methods for using the polypeptides....

Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
01/22/15 - 20150023970 - In certain aspects, the present invention provides compositions and methods for inducing utrophin expression in muscle with an ActRIIB protein as therapy for muscular dystrophy. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand....

Modulation of activity of proneurotrophins
01/22/15 - 20150023971 - The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as...

Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
01/22/15 - 20150023972 - The present invention relates to a combination pharmaceutical composition comprising a) an activated-potentiated form of an antibody to at least one cytokine and b) an activated-potentiated form of an antibody to at least one receptor, and methods of treating and preventing the infectious diseases, including bacterial infections caused by different...

Pharmaceutical compositions for preventing or treating angiogenic diseases comprising inhibitors of nup153 gene expression or nup153 activity as active ingredient
01/22/15 - 20150023973 - The present invention provides a pharmaceutical composition for preventing or treating angiogenic diseases comprising inhibitors of NUP153 gene expression or NUP153 activity as active ingredient and a method for screening an agent for preventing or treating angiogenic diseases. According to the present invention, inhibition of the NUP153 gene expression or...

Toll-like receptor 2 binding epitope and binding member thereto
01/22/15 - 20150023974 - The present invention relates to the identification of a TLR2 binding epitope wherein binding of a binding member to the epitope serves to inhibit TLR2 activation and/or signalling. Polypeptide fragments of TLR2 and three-dimensional structures comprising one or more amino acid residues His318, Pro320, Gln321 or Arg321, Tyr323, Lys347, Phe349,...

Par-1 activation by metalloproteinase-1 (mmp-1)
01/22/15 - 20150023975 - Matrix metalloproteases (MMPs) play many important roles in normal and pathological remodeling processes including atherothrombotic disease, inflammation, angiogenesis and cancer. This invention relates to the activation of protease-activated receptor-1 (PAR-1) by endogenous platelet MMP-1 collagenase on the surface of platelets. Exposure of platelets to fibrillar collagen converts the surface-bound pro-MMP-1...

Antibody polypeptides that antagonize cd40l
01/22/15 - 20150023976 - Antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The antibody polypeptides are useful in the treatment of diseases involving CD40L activation, such as graft-related diseases and autoimmune diseases. The antibody polypeptides may be domain antibodies (dAbs) comprising a single VH or VK...

Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
01/15/15 - 20150017171 - The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of PLVAP proteins, including humanized and chimeric antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising such polypeptide antagonists....

Pharmaceutical composition for treatment and/or prevention of cancer
01/15/15 - 20150017172 - This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof in a therapeutic and/or preventive agent for cancer. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of...

Antibodies to human transmembrane proteins
01/15/15 - 20150017173 - The invention provides human transmembrane proteins (HTMPN) and polynucleotides which identify and encode HTMPN. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with expression of HTMPN....

Inhibitors of complement activation
01/08/15 - 20150010569 - The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including immunoglobulin fragments like Fab, F(ab′)2 and Fv, small molecules, including...

Methods and compositions for using mhc class ii invariant chain polypeptides as a receptor for macrophage migration inhibitory factor
01/08/15 - 20150010570 - Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor,...

Rspo binding agents and uses thereof
01/08/15 - 20150010571 - The present invention relates to RSPO-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human RSPO proteins and modulate β-catenin activity. The present invention further provides methods of using agents that modulate the activity of RSPO proteins,...

Ang-2 specific antibodies and uses thereof
01/08/15 - 20150010572 - Provided are an anti-Ang-2 antibody or antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang-2), related compositions and pharmaceutical compositions, and methods for using such compositions and pharmaceutical compositions....

Lectin-like oxidized ldl receptor 1 antibodies and methods of use
01/01/15 - 20150004168 - The present invention relates to monoclonal antibodies binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as “LOX-1”), and pharmaceutical compositions and methods of treatment comprising the same....

Methods of treating brain injury
01/01/15 - 20150004169 - Embodiments of the invention are directed to compositions and methods related to Tau oligomers and Tau oligomer specific antibodies and their use in detecting and/or treating traumatic brain injury or chronic traumatic encephaly....

Angiogenic and immunologic applications of anti-cd160 specific compounds obtainable from mab cl1-r2
01/01/15 - 20150004170 - The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production....

Pharmaceutical composition for treatment and/or prevention of cancer
01/01/15 - 20150004171 - This invention provides an antibody targeting a cancer antigenic protein specifically expressed on the surface of cancer cells and use thereof in a therapeutic and/or preventive agent for cancers. Specifically, this invention provides an antibody or a fragment thereof which has immunological reactivity with a partial CAPRIN-1 polypeptide consisting of...

Hypoxia-induced mitogenic factor
01/01/15 - 20150004172 - We found that FIZZ1/RELMα is inducible by hypoxia in lung. The hypoxia-upregulated expression of FIZZ1/RELMα was located in the pulmonary vasculature, bronchial epithelial cells, and type II pneumocytes. Recombinant FIZZ1/RELMα protein stimulates rat pulmonary microvascular smooth muscle cell (RPSM) proliferation dose-dependently. Therefore, we renamed this gene as hypoxia-induced mitogenic factor...

Compositions and methods for analyzing histidine phosphorylation
01/01/15 - 20150004173 - A peptide is disclosed of the general structure: Z—W—Y, wherein Z and Y are independently a one to eight amino acid sequence wherein the amino acids are selected from glycine and alanine and W is a non-hydrolyzable pHis analogue. Such peptides can be used to produce sequence-independent anti-phosphohistidine antibodies. Also...

Naturally occurring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
12/25/14 - 20140377271 - The present invention refers to human antibodies which are directed against α-Synuclein (α-Syn) and their use in medicine and diagnosis....

Anti-her3 antibodies and uses thereof
12/25/14 - 20140377272 - The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof....

Anti-her3 antibodies and uses thereof
12/25/14 - 20140377273 - The present invention relates to antibodies binding to human HER3 (anti-HER3 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof....

Erg monoclonal antibodies
12/18/14 - 20140370023 - Monoclonal antibodies, or antigen-binding fragments thereof, that bind to ERG, and more specifically, to an epitope formed by amino acids 42-66 of ERG3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the CDR regions derived from those non-human antibodies. In...

Methods of treating pain by inhibition of vgf activity
12/18/14 - 20140370024 - The present disclosure relates to a method of treating pain, in particular neuropathic pain, comprising administering a therapeutically effective amount of an inhibitor of VGF activity resulting from binding of VGF or a peptide of the type TLQP-21 to the receptor qC1qR. The disclosure also relates to and methods of...

Uses of mammalian cytokines and agonists; related reagents
12/18/14 - 20140370025 - Provided are methods of treatment for tumors. In particular, provided are methods of using of a cytokine molecule and its receptor....

Cytomegalovirus surface protein complex for use in vaccines and as a drug target
12/18/14 - 20140370026 - Immunogenic compositions and prophylactic or therapeutic vaccines for use in protecting and treating against human cytomegalovirus (CMV) are disclosed. Subunit vaccines comprising a human CMV protein complex comprising pUL128 or pUL130, and nucleic acid vaccines comprising at least one nucleic acid encoding a CMV protein complex comprising pUL128 or pUL130...

Neuregulin antibodies and uses thereof
12/11/14 - 20140363438 - The invention provides anti-neuregulin1 antibodies and methods of using the antibodies in treating diseases or disorders, such as cancer. In a particular embodiment, the anti-neuregulin1 antibodies bind to both neuregulin1α and neuregulin 1β isoforms....

Anti-lrp6 antibodies
12/11/14 - 20140363439 - The invention provides anti-LRP6 antibodies and methods of using the same. A particular aspect of the invention provides for bispecific anti-LRP6 antibodies that inhibit signaling by multiple Wnt isoforms....

Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases
12/11/14 - 20140363440 - Anti CMV antibodies are provided. Thus an antibody of the present invention comprises an antigen recognition domain capable of binding an MHC molecule being complexed with a cytomegalovirus (CMV) pp65 or pp64 peptide, wherein the antibody does not bind said MHC molecule in an absence of said complexed peptide, and...

Applications of an immune system-released activating agent (israa)
12/04/14 - 20140356368 - The present invention relates to applications of an immune system-released activating agent (ISRAA) polypeptide, which is induced by a nervous stimulus and which has been found to mediate the transmission of signals between the immune system and the nervous system following an immune challenge. Here, the ISRAA polypeptide is for...

Antibodies to human gdf8
12/04/14 - 20140356369 - The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or...

Method of treating and reducing the risk of acute myelogenous leukemia
11/27/14 - 20140348840 - The present invention relates to methods and compositions for treating and reducing the risk of Acute Myelogenous Leukemia (AML). In particular, the invention provides methods for identifying novel treatments for AML based on reproducible and detectable changes in AML1-ETO acetylation. The present invention further provides methods of using these treatments....

Anti-gitr antibodies
11/27/14 - 20140348841 - Antibodies to human GITR are provided, as well as uses thereof, e.g., in treatment of proliferative and immune disorders....

Tim-3 ligands and methods thereof
11/27/14 - 20140348842 - The invention relates to isolated polypeptides and nucleic acids encoding polypeptides which comprise a tim-3 IgV domain and a tim-3 intracellular domain, wherein the polypeptides do not comprise a tim-3 mucin domain or a tim-3 transmembrane domain. In addition, the invention relates to methods of modulating immune responses in a...

Apoe immunotherapy
11/27/14 - 20140348843 - The present invention provides antibodies that preferentially bind to an ApoE(1-272) fragment relative to ApoE(1-299). These antibodies serve to reduce the toxicity of this fragment and find use in treatment and prophylaxis of a variety of neurological diseases....

Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
11/27/14 - 20140348844 - This present invention describes the derivation and selection of antibodies capable of neutralising the major exotoxins; TcdA and TcdB of Clostridium difficile. The invention also describes novel neutralisation and antigen binding properties of individual Mabs and mixtures thereof....

Anti-human cd52 immunoglobulins
11/20/14 - 20140341910 - The present invention relates to humanized immunoglobulins, mouse monoclonal antibodies and chimeric antibodies that have binding specificity for human CD52. The present invention further relates to a humanized immunoglobulin light chain and a humanized immunoglobulin heavy chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells...

Prevention and treatment of amyloidogenic disease
11/20/14 - 20140341911 - The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is...

Monoclonal antibodies directed to cd52
11/20/14 - 20140341912 - The invention provides antibody to canine or feline or equine antigens, e.g., canine CD52, and methods of making and using antibodies as described....

Methods and compositions for treating asthma using anti-il-13 antibodies
11/20/14 - 20140341913 - The invention provides methods and compositions for treating asthma, e.g., mild or moderate asthma, in a subject using an anti-IL-13 antibody, or antigen-binding portion thereof....

Isolated mcpip and methods of use
11/20/14 - 20140341914 - A monocyte chemoattractant protein (MCP-1)-inducible protein, MCPIP, its polynucleotide and amino acid sequences from mouse and human, and methods for its use are disclosed....

B7-h6 therapeutically active monoclonal antibody against b7-h6 polypeptide
11/20/14 - 20140341915 - The present invention is concerned with diagnostic methods and means. Specifically, it relates to an antibody which specifically binds to a portion of the extracellular domain of the B7-H6 polypeptide. Moreover, said antibody is provided for use in the treatment or diagnosis of cancer or inflammatory disease. Furthermore, provided are...

Therapeutic combinations and methods of treating melanoma
11/20/14 - 20140341916 - The invention provides therapeutic combinations of anti-ETBR antibodies and MAP kinase inhibitors and methods of using the same to treat melanoma....

Anti-pd-l1 antibodies and uses thereof
11/20/14 - 20140341917 - The present application relates to anti-PD-L1 antibodies or antigen binding fragments thereof, nucleic acid encoding the same, therapeutic compositions thereof, and their use to enhance T-cell function to upregulate cell-mediated immune responses and for the treatment of T cell dysfunctional disorders, such as tumor immunity, for the treatment of and...

Vaccine for falciparum malaria
11/20/14 - 20140341918 - The invention provides compositions and methods for preventing or reducing the severity of malaria....

Pharmaceutical composition for treatment and/or prevention of cancer
11/20/14 - 20140341919 - According to the present invention, a cancer antigen protein to be specifically expressed on the surfaces of cancer cells is identified and thus the use of an antibody targeting the cancer antigen protein as an agent for treating and/or preventing a cancer is provided. Specifically, the present invention provides a...

Therapeutic agent for cancer, and method for determining prognosis of cancer
11/13/14 - 20140335090 - Disclosed are a novel therapeutic agent for cancer such as esophageal squamous cell carcinoma, a method for predicting the prognosis of cancer, and a method for detecting, or predicting the prognosis of, cancer such as esophageal squamous cell carcinoma using a sample that can be collected less invasively. The therapeutic...

Anti-glucagon receptor antibodies and methods of use thereof
11/13/14 - 20140335091 - The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose...

Compositions and methods for immunization against drug resistant acinetobacter baumannii
11/13/14 - 20140335092 - The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against A. baumannii infection. The invention also provides antibodies and antigen-binding parts thereof that specifically bind to OmpA, and related methods of passive immunization against A. baumannii infection. The compositions and methods...

Pd-1 antibodies and pd-l1 antibodies and uses thereof
11/13/14 - 20140335093 - The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof....

Mammalian cytokines; related reagents and methods
11/13/14 - 20140335094 - Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided....

Compositions and methods related to protein a (spa) antibodies as an enhancer of immune response
11/13/14 - 20140335095 - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant or an...

Anti-glucagon antibodies and uses thereof
11/13/14 - 20140335096 - Provided are monoclonal antibodies, or antigen-binding fragments thereof, that bind to glucagon. These antibodies are useful in immunoassays of glucagon levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting glucagon levels, and for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens...

Expression vector
11/13/14 - 20140335097 - The present invention provides an expression vector for cell-surface expression of proteins....

Method for treating metabolic disorders
11/06/14 - 20140328848 - The present invention relates to compositions comprising anti-ActRIIB antibodies and use thereof for increasing brown fat in vertebrate, including rodents and primates, and particularly in humans without significantly affecting hematological parameters....

Anti-crth2 antibodies and methods of use
11/06/14 - 20140328849 - The invention provides anti-CRTh2 antibodies and methods of using the same....

Apelin antigen-binding proteins and uses thereof
11/06/14 - 20140328850 - This disclosure relates to apelin antigen-binding proteins and methods of using the apelin antigen-binding proteins. The antigen-binding protein may comprise an antibody to apelin and can be used to treat pathological conditions involving angiogenesis. The pathological conditions can comprise cancer or retinopathy and/or retinopathy-related complications....

Cholesterol ester transfer protein (cetp) inhibitor polypeptide antibodies for prophylactic and therapeutic anti-atherosclerosis treatments
11/06/14 - 20140328851 - Herein are described two antibodies that can inhibit CETP-lipoproteins interaction and CETP activity. Presently described are an antibody or fragment thereof capable of specifically binding to an epitope of the N-terminal or C-terminal domains of CETP and methods of using these antibodies for separation, identification, diagnosis and therapy....

Immunogenic gluten peptides and uses thereof
11/06/14 - 20140328852 - The invention relates to an immunogenic peptide of eight amino acids that is generated naturally in the intestine of celiac patients by means of the hydrolysis of ingested gluten. In addition, the invention relates to the use of the peptide, or antibodies generated against same, for the in vitro monitoring...

Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
11/06/14 - 20140328853 - Subject matter of the present invention is an anti-adrenomedullin (ADM) antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold for use in therapy of a chronical or acute disease or acute condition of a patient for prevention or reduction of organ dysfunction or organ failure. In a preferred...

Compounds and methods for the modulation of beta-1 integrin function to mediate tissue repair
10/30/14 - 20140322222 - The present invention provides methods and compositions that modulate beta 1 integrin activity by functioning as allosteric antagonists. In particular, the present invention provides methods for mediating tissue repair where insult or injury has occurred by antagonising the allosteric function of beta 1 integrin....

Tox3 as a biomarker for breast cancer
10/30/14 - 20140322223 - The invention provides compositions and methods for detecting and/or modulating TOX3 gene expression and/or biological activity. Such compositions and methods find utility in the detection and/or treatment of certain subsets of cancers, e.g. breast cancer. In particular, the inventive compositions and methods are drawn to production and use of anti-TOX3...

Monoclonal antibodies against serotransferrin antigens, and uses therefor
10/30/14 - 20140322224 - The invention relates to monoclonal antibodies (mAbs) that bind to serotransferrin (TF), hybridoma lines that secrete these antibodies or fragments thereof, and the use of these antibodies to detect TF antigens. Methods and uses for detecting prostate cancer, as well as methods and uses for distinguishing early and late stage...

Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
10/30/14 - 20140322225 - In a preferred embodiment anti-ADM antibody or an anti-adrenomedullin antibody fragment or an anti-ADM non-Ig scaffold according to the present invention reduces the vasopressor requirement, e.g. catecholamine requirement of said patient. The catecholamine requirement of a patient is an indicator for the condition of the circulation and hemodynamic function of...

Methods for treating visceral pain by administering antagonist antibodies directed against calcitonin gene-related peptide
10/23/14 - 20140314767 - The invention features methods for preventing or treating visceral pain, including pain associated with functional bowel disorder, inflammatory bowel disease and interstitial cystitis, by administering an anti-CGRP antagonist antibody....

Methods and compositions for treating and diagnosing diseases
10/23/14 - - Methods and compositions for diagnosing and treating diseases, particularly cancer, associated with differential expression of cancer-associated targets (CAT) in disease cells compared to healthy cells are provided. Also provided are antagonists and agonists of CAT, and methods for screening agents that modulate CAT level or activity in vivo or in...

Neutralizing antibodies and methods of use thereof
10/23/14 - 20140314769 - This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins,...

Kidney disease targets and uses thereof
10/23/14 - 20140314770 - The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as...

Combination therapy of antibodies against human csf-1r and tlr9 agonist
10/23/14 - 20140314771 - The present invention relates to the combination therapy of antibodies against human CSF-1R with a TLR9 agonist....

Anti-c5a binding moieties with high blocking activity
10/23/14 - 20140314772 - The present invention relates to binding moieties that specifically bind to a conformational epitope of C5a, in particular human C5a. Preferred binding moieties are anti-C5a antibodies that bind to this conformational epitope. The binding moieties described herein are useful as active agents in pharmaceutical compositions for the treatment and prevention...

Compositions and methods for treating alzheimer's disease
10/23/14 - 20140314773 - The present disclosure provides for a hyperimmune preparation comprising human polyclonal antibodies or fragments thereof specific to a cyclic peptide having an amino acid sequence comprising SNK. The cyclic peptide may comprise an amino acid sequence GSNK (SEQ ID NO: 1), SNKG(SEQ ID NO: 2), GSNKG (SEQ ID N0:3), CSNKG...

Her3 antibodies and uses thereof
10/23/14 - 20140314774 - Provided herein are antibodies specific for HER3. Also provided are methods of treating cancer in a subject comprising administering an effective amount of the antibodies described herein to the subject....

Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment of anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
10/23/14 - 20140314775 - Patients having a chronic or acute disease or acute condition, especially patients at the ICU (Intensive Care Unit) suffer from fluid imbalance. The present invention provides a medicament for regulating the fluid balance and/or improving the fluid balance of such patients. Subject matter of the present invention is an anti-Adrenomedullin...

Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
10/23/14 - 20140314776 - The invention provides a method of treating alveolar bone loss involving administration of a sclerostin inhibitor to a subject in need thereof....

Monoclonal antibodies targeting neutralizing epitopes on h5 influenza virus of clade 2.3
10/23/14 - 20140314777 - The present invention relates to murine monoclonal antibodies C, F and H which target major neutralizing epitopes of influenza H5 hemagglutinin of clade 2.3 and active fragments thereof. The present invention also relates to methods and compositions for the prophylaxis and treatment of H5N1 influenza using murine monoclonal antibodies C,...